{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:04:45Z","timestamp":1789383885482,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40487-026-00455-6","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:51:39Z","timestamp":1782647499000},"page":"1025-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IMMPACT-MM: Insights into Multiple Myeloma Patient Outcomes\u00a0following Early-Line Cilta-cel Treatment"],"prefix":"10.1007","volume":"14","author":[{"given":"Sridevi","family":"Rajeeve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh P.","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"7","key":"455_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072160","volume":"15","author":"D Dima","year":"2023","unstructured":"Dima D, Ullah F, Mazzoni S, et al. Management of relapsed-refractory multiple myeloma in the era of advanced therapies: evidence-based recommendations for routine clinical practice. Cancers (Basel). 2023;15(7):2160. https:\/\/doi.org\/10.3390\/cancers15072160.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"455_CR2","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322\u201347. https:\/\/doi.org\/10.3390\/curroncol30020179.","journal-title":"Curr Oncol"},{"issue":"9","key":"455_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94. https:\/\/doi.org\/10.1038\/s41408-020-00359-2.","journal-title":"Blood Cancer J"},{"issue":"2","key":"455_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11523-024-01122-4","volume":"20","author":"S Mettias","year":"2025","unstructured":"Mettias S, ElSayed A, Moore J, Berenson JR. Multiple myeloma: improved outcomes resulting from a rapidly expanding number of therapeutic options. Target Oncol. 2025;20(2):247\u201367. https:\/\/doi.org\/10.1007\/s11523-024-01122-4.","journal-title":"Target Oncol"},{"issue":"5","key":"455_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31(5):667\u201386. https:\/\/doi.org\/10.1038\/s41417-024-00750-2.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"455_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41409-025-02782-0","volume":"61","author":"T de Soto","year":"2026","unstructured":"de Soto T, Moukalled N, Mohty M. Toward functional cure in relapsed\/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells. Bone Marrow Transplant. 2026;61(3):253\u20134. https:\/\/doi.org\/10.1038\/s41409-025-02782-0.","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"455_CR7","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.1182\/blood-2025-7605","volume":"146","author":"HMH Javed","year":"2025","unstructured":"Javed HMH, Shahid H, Ashraf F, Mushtaq MU, Shahzad M. CAR-T cell therapy in multiple myeloma in a front-line setting: A systematic review and meta-analysis. Blood. 2025;146(Supplement 1):7605\u20137605. https:\/\/doi.org\/10.1182\/blood-2025-7605.","journal-title":"Blood"},{"issue":"12","key":"455_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/14656566.2022.2101362","volume":"23","author":"V Sunder-Plassmann","year":"2022","unstructured":"Sunder-Plassmann V, Aksoy O, Lind J, Pecherstorfer M, Vallet S, Podar K. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future. Expert Opin Pharmacother. 2022;23(12):1425\u201344. https:\/\/doi.org\/10.1080\/14656566.2022.2101362.","journal-title":"Expert Opin Pharmacother"},{"issue":"14","key":"455_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","volume":"15","author":"A Medina-Herrera","year":"2023","unstructured":"Medina-Herrera A, Sarasquete ME, Jimenez C, Puig N, Garcia-Sanz R. Minimal residual disease in multiple myeloma: past, present, and future. Cancers (Basel). 2023;15(14):3687. https:\/\/doi.org\/10.3390\/cancers15143687.","journal-title":"Cancers (Basel)"},{"issue":"23","key":"455_CR10","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988\u201399. https:\/\/doi.org\/10.1182\/bloodadvances.2020002827.","journal-title":"Blood Adv"},{"issue":"23","key":"455_CR11","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140(23):2423\u20138. https:\/\/doi.org\/10.1182\/blood.2022016170.","journal-title":"Blood"},{"issue":"8","key":"455_CR12","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"15","key":"455_CR13","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/1078-0432.CCR-22-3579","volume":"29","author":"AC Baines","year":"2023","unstructured":"Baines AC, Yazdy MS, Kasamon YL, et al. Minimal residual disease data in hematologic malignancy drug applications and labeling: an FDA perspective. Clin Cancer Res. 2023;29(15):2748\u201352. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3579.","journal-title":"Clin Cancer Res"},{"key":"455_CR14","unstructured":"US Food and Drug Administration. Minimal residual disease and complete response in multiple myeloma: use as endpoints to support accelerated approval. January 2026. https:\/\/www.fda.gov\/media\/190647\/download. Accessed 27 Mar 2026."},{"issue":"2","key":"455_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","volume":"27","author":"H Einsele","year":"2026","unstructured":"Einsele H, San-Miguel J, Dhakal B, et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2026;27(2):254\u201368. https:\/\/doi.org\/10.1016\/S1470-2045(25)00653-9.","journal-title":"Lancet Oncol"},{"issue":"25","key":"455_CR16","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43(25):2766\u201371. https:\/\/doi.org\/10.1200\/JCO-25-00760.","journal-title":"J Clin Oncol"},{"issue":"4","key":"455_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"key":"455_CR18","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2025.16.7.25","author":"YL Hwa","year":"2025","unstructured":"Hwa YL, Doss D, Mangan PA, Faber MC, Catamero DD. Understanding the role and clinical management of bridging therapy during CAR T-Cell therapy for relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2025. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.25.","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"455_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","volume":"10","author":"M Ventin","year":"2024","unstructured":"Ventin M, Cattaneo G, Maggs L, Arya S, Wang X, Ferrone CR. Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review. JAMA Oncol. 2024;10(1):115\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4504.","journal-title":"JAMA Oncol"},{"issue":"21","key":"455_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood"},{"issue":"5","key":"455_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359. https:\/\/doi.org\/10.1056\/NEJMoa1709919.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"455_CR22","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1182\/blood-2025-2215","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Iida S, Sidiqi MH, et al. Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. Blood. 2025;146(Supplement 1):2215\u20132215. https:\/\/doi.org\/10.1182\/blood-2025-2215.","journal-title":"Blood"},{"issue":"Suppl 1","key":"455_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jha2.335","volume":"3","author":"ST Bhaskar","year":"2022","unstructured":"Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022;3(Suppl 1):39\u201345. https:\/\/doi.org\/10.1002\/jha2.335.","journal-title":"EJHaem"},{"key":"455_CR24","unstructured":"Janssen Biotech I. CARVYKTI\u00ae (ciltacabtagene autoleucel) prescribing information. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf. Accessed 9 Jan 2026."},{"issue":"11","key":"455_CR25","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"key":"455_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/cci.19.00094","volume":"4","author":"BG Patel","year":"2020","unstructured":"Patel BG, Luo S, Wildes TM, Sanfilippo KM. Frailty in older adults with multiple myeloma: a study of US veterans. JCO Clin Cancer Inform. 2020;4:117\u201327. https:\/\/doi.org\/10.1200\/cci.19.00094.","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"455_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07077-9","volume":"20","author":"T Ching","year":"2020","unstructured":"Ching T, Duncan ME, Newman-Eerkes T, et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20(1):612. https:\/\/doi.org\/10.1186\/s12885-020-07077-9.","journal-title":"BMC Cancer"},{"issue":"10","key":"455_CR28","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u2013103. https:\/\/doi.org\/10.1038\/leu.2017.29.","journal-title":"Leukemia"},{"issue":"2","key":"455_CR29","doi-asserted-by":"publisher","first-page":"S416","DOI":"10.1016\/j.jtct.2025.12.597","volume":"32","author":"BJ Kale","year":"2026","unstructured":"Kale BJ, Kaldas D, Lee L, et al. Day 90 NGS-based MRD negativity predicts survival after BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Transplant Cell Ther. 2026;32(2):S416. https:\/\/doi.org\/10.1016\/j.jtct.2025.12.597.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"455_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01461-7","volume":"16","author":"M Mohty","year":"2026","unstructured":"Mohty M, Malard F, Facon T, Harousseau JL. Toward a cure for multiple myeloma within a decade. Blood Cancer J. 2026;16(1):33. https:\/\/doi.org\/10.1038\/s41408-026-01461-7.","journal-title":"Blood Cancer J"},{"issue":"6","key":"455_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","volume":"22","author":"B Paiva","year":"2025","unstructured":"Paiva B, Shi Q, Puig N, et al. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nat Rev Clin Oncol. 2025;22(6):424\u201338. https:\/\/doi.org\/10.1038\/s41571-025-01017-x.","journal-title":"Nat Rev Clin Oncol"},{"issue":"S1","key":"455_CR32","doi-asserted-by":"publisher","first-page":"PB2944","DOI":"10.1002\/2Fhem3.70153","volume":"9","author":"J Artzenroth","year":"2025","unstructured":"Artzenroth J, Alsdorf W, Al-Bazaz M, et al. Real-world data on bridging strategies, toxicity and outcomes of relapsed\/refractory multiple myeloma patients treated with CAR-T cells. HemaSphere. May2025;9(S1):PB2944. https:\/\/doi.org\/10.1002\/2Fhem3.70153.","journal-title":"HemaSphere"},{"key":"455_CR33","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2025-2214","volume":"146","author":"D Hansen","year":"2025","unstructured":"Hansen D, Reid B, Grajales-Cruz A, et al. Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma. Blood. 2025;146:2214. https:\/\/doi.org\/10.1182\/blood-2025-2214.","journal-title":"Blood"},{"issue":"1","key":"455_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14(1):63. https:\/\/doi.org\/10.1038\/s41408-024-00993-0.","journal-title":"Blood Cancer J"},{"issue":"17","key":"455_CR35","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.2025029773","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Akhtar OS, Fandrei D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025;146(17):2063\u201372. https:\/\/doi.org\/10.1182\/blood.2025029773.","journal-title":"Blood"},{"issue":"Supplement 1","key":"455_CR36","doi-asserted-by":"publisher","first-page":"6262","DOI":"10.1182\/blood-2025-6262","volume":"146","author":"T Nishihori","year":"2025","unstructured":"Nishihori T, Kaur M, Langerman S, Fullerton C, Ahmed S. Barriers and bridges: real-world CAR T delivery across US oncology practices. Blood. 2025;146(Supplement 1):6262. https:\/\/doi.org\/10.1182\/blood-2025-6262.","journal-title":"Blood"},{"key":"455_CR37","unstructured":"TALVEY\u2122 (talquetamab-tgvs). Highlights of prescribing information. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf. Accessed April 2, 2026"},{"issue":"Supplement 1","key":"455_CR38","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2025-4586","volume":"146","author":"M Rana","year":"2025","unstructured":"Rana M, Jensen A, Velayati A, et al. Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in relapsed\/refractory multiple myeloma (RRMM). Blood. 2025;146(Supplement 1):4586\u20134586. https:\/\/doi.org\/10.1182\/blood-2025-4586.","journal-title":"Blood"},{"key":"455_CR39","unstructured":"Kumar S, Callander N, Adekola K, et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Multiple Myeloma (Version 5.2026\u2014January 9, 2026). 2026. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"issue":"Supplement 1","key":"455_CR40","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1182\/blood-2025-4596","volume":"146","author":"D Hansen","year":"2025","unstructured":"Hansen D, Castaneda Puglianini OA, Grajales-Cruz A, et al. Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma. Blood. 2025;146(Supplement 1):4596\u20134596. https:\/\/doi.org\/10.1182\/blood-2025-4596.","journal-title":"Blood"},{"key":"455_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-026-00433-y","author":"S Sidana","year":"2026","unstructured":"Sidana S, Nagar SP, Ghosh S, et al. Real-world description of non-ICANS neurologic events among patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel using two large US databases. Oncol Ther. 2026. https:\/\/doi.org\/10.1007\/s40487-026-00433-y.","journal-title":"Oncol Ther"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00455-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00455-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00455-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:32:23Z","timestamp":1789381943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00455-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00455-6","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sridevi Rajeeve received honoraria from Johnson & Johnson and research support from Johnson & Johnson, BMS, C4 Therapeutics, Heidelberg Pharma, and Gracell Biotechnologies; and is also part of BMS advisory board\/steering committee of Gracell Biotechnologies. Saurabh P. Nagar, Sabyasachi Ghosh, Victoria Alegria, and Zaina P. Qureshi are employees and stockholders of Johnson & Johnson. Justin Hayne is an employee of Legend Biotech and owns stock\/stock options in Legend Biotech. Bruno Emond and Jessica Maitland are employees of Analysis Group ULC, a consulting company that has provided paid consulting services to Johnson & Johnson. Larry D. Anderson Jr. has provided consultancy to Bristol-Myers-Squibb, Celgene, Arcellx\/Kite, Karyopharm, GlaxoSmithKline, AbbVie, Johnson & Johnson, Prothena, Sanofi, Beigene, Cellectar Biosciences, and Amgen; received research funding from Bristol-Myers-Squibb, Celgene, AbbVie, and Cellectar Biosciences; received honoraria from Bristol-Myers-Squibb, Celgene, Arcellx\/Kite, GlaxoSmithKline, Johnson & Johnson, Prothena, Sanofi, Pfizer, Beigene, Cellectar Biosciences, and Amgen; and participated in a Board of Directors or Advisory Committee for Celgene, Arcellx\/Kite, GlaxoSmithKline, AbbVie, Karyopharm, Johnson & Johnson, Prothena, Sanofi, Pfizer, Beigene, Cellectar Biosciences, and Amgen.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was considered exempt from review by an institutional review board as it involved only the secondary use of fully de-identified data in compliance with HIPAA, specifically, 45 CFR \u00a7 164.514. Additionally, this study did not involve interaction with human subjects or access to identifiable private information. All structured and unstructured data, including physician notes, were de-identified by Loopback Analytics prior to access by the study team or third-party data abstractor, and no identifiable patient information was available to investigators at any time. Loopback Analytics\u2019 de-identification process included removal and obfuscation of protected health information in accordance with HIPAA standards, including removal or transformation of HIPAA identifiers and replacement of direct identifiers with synthetic surrogates using a \u201chiding in plain sight\u201d methodology. Accordingly, the study was considered exempt under 45 CFR \u00a7 46.104(d)(4).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}